Publications en collaboration avec des chercheurs de Universidad Autónoma de Madrid (53)

2023

  1. Imbalance in Bone Morphogenic Proteins 2 and 7 Is Associated with Renal and Cardiovascular Damage in Chronic Kidney Disease

    International Journal of Molecular Sciences, Vol. 24, Núm. 1

  2. Prevention of cardiorenal damage: importance of albuminuria

    European heart journal, Vol. 44, Núm. 13, pp. 1112-1123

2022

  1. IMBALANCE IN BONE MORPHOGENIC PROTEINS 2 AND 7 IS ASSOCIATED WITH HYPERTENSION AND ARTERIAL STIFFNESS IN CHRONIC KIDNEY DISEASE

    Journal of hypertension, Vol. 40, pp. e81

2020

  1. Differential metabolic profile associated with the condition of normoalbuminuria in the hypertensive population

    Nefrologia, Vol. 40, Núm. 4, pp. 439-445

  2. Urinary metabolic signatures reflect cardiovascular risk in the young, middle-aged, and elderly populations

    Journal of Molecular Medicine, Vol. 98, Núm. 11, pp. 1603-1613

2019

  1. Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients

    Nefrologia, Vol. 39, Núm. 2, pp. 184-191

  2. Lifetime cardiovascular risk is associated with a multimarker score of systemic oxidative status in young adults independently of traditional risk factors

    Translational Research, Vol. 212, pp. 54-66

2017

  1. Rapid, automated, and specific immunoassay to directly measure matrix metalloproteinase-9-tissue inhibitor of metalloproteinase-1 interactions in human plasma using AlphaLISA technology: A new alternative to classical ELISA

    Frontiers in Immunology, Vol. 8, Núm. JUL

2016

  1. Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppression

    Cardiovascular Diabetology, Vol. 15, Núm. 1

2014

  1. Comparison of agents that affect aldosterone action

    Seminars in Nephrology, Vol. 34, Núm. 3, pp. 285-306

  2. Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression

    Journal of Hypertension, Vol. 32, Núm. 10, pp. 2082-2091

  3. Diuretics in the treatment of hypertension. Part 1: Thiazide and thiazide-like diuretics

    Expert Opinion on Pharmacotherapy, Vol. 15, Núm. 4, pp. 527-547

  4. Diuretics in the treatment of hypertension. Part 2: Loop diuretics and potassium-sparing agents

    Expert Opinion on Pharmacotherapy, Vol. 15, Núm. 5, pp. 605-621

  5. Night-time heart rate cut-off point definition by resting office tachycardia in untreated hypertensive patients: Data of the Spanish ABPM registry

    Journal of Hypertension, Vol. 32, Núm. 5, pp. 1016-1024

  6. Resistant hypertension and renal denervation. Considerations on the results of the SYMPLICITY HTN-3 trial

    Revista Espanola de Cardiologia, Vol. 67, Núm. 11, pp. 881-882

2013

  1. Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension

    Current Hypertension Reports, Vol. 15, Núm. 3, pp. 196-203

  2. Resistant hypertension: From prevention to renal denervation

    Medicina Clinica, Vol. 141, Núm. 1, pp. 27-28

2011

  1. Abnormalities in ambulatory blood pressure monitoring in hypertensive patients with diabetes

    Hypertension Research, Vol. 34, Núm. 11, pp. 1185-1189

  2. New clinical concepts after the ONTARGET trial

    Expert Review of Cardiovascular Therapy, Vol. 9, Núm. 6, pp. 685-689

2009

  1. Control of hypertension in coronary heart disease

    International Journal of Cardiology, Vol. 134, Núm. 2, pp. 245-247